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Although G protein-coupled receptor (GPCR) internalization has long been considered 
as a major aspect of the desensitization process that tunes ligand responsiveness, 
internalization is also involved in receptor resensitization and signaling, as well as the 
ligand scavenging function of some atypical receptors. Internalization thus contributes to 
the diversity of GPCR-dependent signaling, and its dynamics and quantification in living 
cells has generated considerable interest. We developed a robust and sensitive assay 
to follow and quantify ligand-induced and constitutive-induced GPCR internalization but 
also receptor recycling in living cells. This assay is based on diffusion-enhanced reso-
nance energy transfer (DERET) between cell surface GPCRs labeled with a luminescent 
terbium cryptate donor and a fluorescein acceptor present in the culture medium. GPCR 
internalization results in a quantifiable reduction of energy transfer. This method yields 
a high signal-to-noise ratio due to time-resolved measurements. For various GPCRs 
belonging to different classes, we demonstrated that constitutive and ligand-induced 
internalization could be monitored as a function of time and ligand concentration, thus 
allowing accurate quantitative determination of kinetics of receptor internalization but 
also half-maximal effective or inhibitory concentrations of compounds. In addition to its 
selectivity and sensitivity, we provided evidence that DERET-based internalization assay 
is particularly suitable for characterizing biased ligands. Furthermore, the determination 
of a Z′-factor value of 0.45 indicates the quality and suitability of DERET-based inter-
nalization assay for high-throughput screening (HTS) of compounds that may modulate 
GPCRs internalization.
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INtRodUCtIoN
G protein-coupled receptors (GPCRs) are membrane proteins that 
respond to a wide variety of extracellular stimuli and play criti-
cal roles in intercellular communication (1). They are central to 
many physiological and pathological processes and represent one 
of the most important classes of drug targets. Classically, agonist-
induced GPCR activation results in the activation of heterotrim-
eric G proteins and the accumulation of second messengers such 
as Ca2+, cyclic AMP, or inositol phosphates. During continuous 
agonist stimulation, GPCR activation diminishes through a 
process known as desensitization, which operates directly at the 
receptor and downstream. Desensitization is typically controlled 
by receptor phosphorylation mediated by kinases, including the 
family of GPCR kinases, which promotes the recruitment of 
β-arrestins to the receptor. In many cases, these processes also lead 
to receptor internalization, which generally proceeds by either a 
clathrin-coated pit or caveolae-mediated pathway (2). However, 
GPCR internalization is also known to promote receptor-medi-
ated signaling and resensitization. Indeed, recent studies have 
shown that internalized GPCRs can continue to either stimulate 
or inhibit cAMP production in a sustained manner (3). Moreover, 
internalization also participates in the ligand-scavenging function 
of atypical GPCRs that constitutively cycle between the plasma 
membrane and intracellular compartments (4). Receptor inter-
nalization is a ubiquitous process and an indicator of activation 
for a wide variety of GPCRs including orphan receptors. Thus, 
internalization contributes to the diversity of GPCR-dependent 
signaling pathways and its dynamics in living cells has generated 
considerable interest. Although fluorescence microscopy permits 
the disappearance of labeled proteins from the cell membrane 
to be visualized, signals from labeled internalized receptors in 
intracellular compartments can also be detected, which can bias 
observations (5). Other techniques for directly measuring recep-
tor internalization include Enzyme-Linked immunoabSorbent 
Assay (ELISA) and flow cytometry (6), but they are poorly suited 
for dynamic analyses due to the numerous washing steps involved 
in these methods, notably harsh treatments (e.g., acidic wash) 
to dissociate ligands from their receptors. Moreover, because 
only a small fraction of the receptors at the cell surface for any 
particular type GPCR undergo internalization, methods must be 
selective and sensitive to be precise. Hence, sensitive plate-based 
assays with high signal-to-background ratios have appeared 
for quantifying β-arrestin recruitment using bioluminescence 
resonance energy transfer (BRET) technology (7) or enzyme 
fragment complementation (8, 9) or for determining the extent 
of receptor internalization by monitoring changes in fluorescence 
resonance energy transfer (FRET) (10). Additionally, alternative 
strategies based on the quenching of internalized receptor tagged 
with a pH-sensitive fluorescent protein probes (11), NanoLuc® 
luciferase (12), or fluorogen activating protein (FAP) have also 
been used to monitor internalization (13).
Here, we extended the use of a single labeling method, 
which displays the requested sensitivity compatible with high-
throughput screening (HTS) for the dynamic and quantitative 
analysis of GPCR internalization. This diffusion-enhanced 
resonance energy transfer (DERET) method relies on the use of 
a luminescent terbium cryptate derivative that irreversibly labels 
cells expressing SNAP-tagged (ST) GPCRs. The ST is a derivative 
of O6-guanine nucleotide alkyltransferase, which can covalently 
react with fluorescent-conjugated benzyl guanine substrates (14). 
To validate the DERET as a reliable and quantitative assay for 
analysis of constitutive- and ligand-induced receptor internaliza-
tion, we compared it to classic techniques for various GPCRs 
from the class A such as the vasopressin V1a and δ opioïd recep-
tors and the two receptors of the CXCL12 chemokine (CXCR4 
and ACKR3/CXCR7; named CXCR7 throughout the text), and 
from the class C such as the metabotropic glutamate receptors 5 
(mGluR5) receptors.
MAteRIALs ANd Methods
Reagents, Plasmids, and Cell Lines
The Tag-lite® labeling medium (catalog reference LABMED) 
and SNAP-Lumi4®-Tb (catalog reference SSNPTBX) SNAP-tag 
(ST) fusion labeling system were conceived and synthesized 
by Cisbio Bioassays (Codolet, France). The 96-well plates and 
384 small volume-well plates were purchased from Greiner 
Bio-One (Monroe, NC, USA). CXCL12 was provided by Dr. F. 
Baleux (Institut Pasteur, Paris, France). Arginine-Vasopressin 
(AVP) was from Bachem and SR49059 was a gift from Sanofi. 
Naloxone, SNC162, and SNC80 were obtained from Tocris 
Bioscience (Bristol, UK). Naltrindole, naltrexazone, methadone, 
morphine, DAMGO, glutamate, fluorescein, AMD3100 and 
poly-l-ornithine (MW of 30,000–70,000 Da) were from Sigma-
Aldrich (St. Louis, MO, USA). Chalcone 4 was a gift from Dr. 
Bonnet, UMR7200, University of Strasbourg, Illkirch, France. 
Lipofectamine 2000 was purchased from Life Technologies 
(Cergy Pontoise, France). To obtain pRK5–Flag-ST–CXCR7 
and –CXCR4 plasmids, the respective coding sequences in the 
pTRIP–CXCR7 and pTRIP–CXCR4 vectors (15) were amplified 
by PCR and inserted in the pRK5–Flag-ST–GB2 plasmid (gift 
from Dr. Pin, Institut de Génomique fonctionnelle, Montpellier, 
France) previously digested with MluI and HindIII to remove the 
GB2 coding sequence. The plasmid encoding the Flag-ST human 
CXCR7ΔCter truncated of 41 C-terminal residues (Δ322–363) 
was generated and provided by Cisbio Bioassays. HEK-293 cells 
stably expressing ST CXCR4 (catalog reference C1SU1CXCR4) 
and ST CXCR7 (catalog reference C1SU1CXCR7), ST V1a (cata-
log reference C1PU1V1A), ST V2 (catalog reference C1PU1V2) 
and CHO cells stably expressing ST δ opioïd receptor (catalog 
reference C2SU1DOP) were provided by Cisbio Bioassays. 
ST-receptors constructs used in this study have been described in 
previous reports and showed no alteration of their pharmacologi-
cal and functional properties (14, 16–18).
Cell Culture and transient transfections
For the analyses of CXCR4, CXCR7, V1a, mGluR5, and δ opioid 
receptors, HEK-293 or CHO cells were grown at 37°C, 5% CO2 in 
complete culture medium (Dulbecco’s Modified Eagle’s Medium 
or HAM-F12 Medium, respectively, supplemented with 10% 
(v/v) fetal bovine serum, 4.5  g/l glucose, 100  U/ml penicillin, 
0.1 mg/ml streptomycin, 1 mM glutamine, and 20 mM HEPES) 
November 2015 | Volume 6 | Article 1673
Levoye et al. Universal Internalization Assay for GPCRs
Frontiers in Endocrinology | www.frontiersin.org
(all reagents were obtained from Life Technologies). Cells stably 
expressing ST receptors were grown in complete culture medium 
supplemented with 0.6  mg/ml geneticin. Transient expression 
in HEK-293T cells was achieved using the transfection reagent, 
FuGene 6 (Roche, Basel, Switzerland) or by reverse transfection 
using Lipofectamine 2000 (Life Technologies). Briefly, for the 
reverse transfection, 96-well plates were coated with poly-
l-ornithine (50 μl of 10 mg/ml) for 30 min at 37°C. After washing, 
transfection mixes were added to the plate and pre-incubated for 
20 min at room temperature. Then, 1–2 × 103 cells were plated in 
each well and incubated at 37°C under 5% CO2 for 24 h.
deRet Internalization Assay
Internalization assays for CXCR4 and CXCR7 were performed 
in 96-well culture cell plates using HEK-293T cells as described 
above. For transient transfection, cell culture medium was 
removed 24 h after transfection and 100 nM of SNAP-Lumi4-Tb 
previously diluted in Tag-lite labeling medium was added (50 μl 
per well) and further incubated for 1  h at 4°C. Excess SNAP-
Lumi4-Tb was removed by washing each well four times with 
100 μl of Tag-lite labeling medium. Internalization experiments 
were performed by incubating cells with Tag-lite labeling 
medium, either alone or containing CXCL12, in the presence 
of fluorescein. Typically, in plates containing SNAP-Lumi4-
Tb-labeled cells, 50  μl of medium containing CXCL12 at the 
indicated concentrations was added, immediately followed by 
the addition of 50 μl of 48 μM fluorescein. ST-V1a receptor inter-
nalization assay was monitored as described below. ST-δ opioïd 
receptor internalization was monitored at room temperature on 
a CHO cell line stably expressing the receptor in either 96-well 
plates (1 × 105 adherent cells per well) or 384 small volume well 
plates (5 × 103 cells in suspension per well). ST-δ opioid receptor 
labeling and internalization measurement following addition 
of δ opioïd ligands (the agonists SNC162, SNC80, morphine, 
methadone, and the antagonists naloxone, naltrindole, and nal-
trexazone) but also μ opioïd ligand such as the agonist DAMGO 
(17) were done as described above.
V1a Labeling, expression, Internalization, 
and Recycling at the Cell surface
Surface expressed V1a in HEK-293 stably expressing the recep-
tor were labeled with SNAP-Lumi4-Tb substrate for 1 h at 4°C. 
The excess of SNAP-Lumi4-Tb was then removed by washing 
each well three times with Tag-lite labeling medium. For kinetic 
internalization experiments, cells were stimulated with 1  μM 
and receptor expression levels determined at 37°C by measur-
ing the SNAP-Lumi4-Tb fluorescence intensity at 620 nm over 
time. Dose–response experiments were performed on cells in the 
presence of increasing concentrations of AVP. Receptor expres-
sion levels were then evaluated after 1 h of incubation at 37°C. 
Real-time recycling of V1a was analyzed by stimulating cells with 
the agonist AVP and the antagonist SR49059. Forty-five minutes 
following AVP addition, SR49059 was added to block receptors 
internalization and to detect any recycled ST-V1a receptors at the 
cell surface.
Fluorescence Microscopy
Cells expressing ST-δ receptor and ST–CXCR7 expressing 
cells were seeded in 8-well slides for 24  h. Cell surface ST-δ 
receptor molecules were labeled during for 30  min with the 
cell-impermeable O6-benzylguanine derivative cell impermeable 
SNAP-Alexa Fluor 488 (New England Biolabs, Ipswich, MA, 
USA) at room temperature. Cells were washed three times with 
Krebs/Tris buffer and incubated for 30 min with either Tag-lite 
medium either alone or containing SNC162 (10 μM) or naloxone 
(10 μM). ST–CXCR7 cells were labeled for 1 h with SNAP-red 
(Cisbio Bioassays) at 4°C and then warmed to 37°C for 1 h to 
visualize constitutive internalization. Fluorescence was detected 
on a Zeiss fluorescent microscope with a xenon flash lamp using 
a GFP or Cy5 filter cube and a Zeiss Plan Apo 63× (1.40 oil) 
objective.
data Presentation and Analysis
Signals emitted at 620 and 520 nm were collected at the indicated 
times using time-resolved settings for the donor (1500 μs delay, 
1500 μs reading time) and acceptor (150 μs delay, 400 μs reading 
time). Ratio 620/520 (R) was obtained by dividing the donor 
signal (620  nm) by the acceptor signal (520  nm) at a chosen 
time and multiplying this value by 10,000. Data are expressed as 
percent of maximal internalization [“% of max. internalization 
(620/520 nm)”] and were calculated using the following formula: 
[(Rt – Rmin)/(Rmax – Rmin)] × 100 where Rt corresponds to the ratio 
observed at a chosen time. Dose–response curves were fitted 
using non-linear regression dose–response “log [ligand] versus 
responses (with three parameters except for CXCR7)” routine of 
Prism 5 (GraphPad Software, La Jolla, CA, USA) to provide the 
maximal (Emax) and half maximal effective concentration EC50 
values. The half-time (t1/2) determination for internalization of 
the V1a receptor was made by fitting data using a single-phase 
exponential decay equation with Prism 5 (GraphPad Software, 
La Jolla, CA, USA).
ResULts ANd dIsCUssIoN
In this study, we used a time-resolved FRET-based receptor 
internalization assay to characterize the dynamics of vasopressin, 
opioïd, chemokine, and glutamate receptors internalization 
in real-time in response to different ligand concentrations. 
Lanthanide-based resonance energy transfer techniques such 
as HTRF (19) have become the standard for high-performance 
assays in GPCR activation, mainly due to the millisecond lifetime 
of the lanthanide excited state and the possibility to reduce cellular 
background emission (20–22). An interesting phenomenon of 
luminescent lanthanide complexes is that, due to their elevated 
millisecond excited-state lifetimes, collisional quenching of 
their luminescence by acceptor chromophores occurs at low 
concentrations. This DERET (23–25) phenomenon has already 
been used to detect electrostatic interactions on proteins (26, 
27) and to monitor translocation of lanthanide complexes (10, 
28). DERET depends on, among other things, the acceptor 
concentration and the shortest possible proximity that can occur 
between the donor and acceptor (23). The DERET was developed 
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to be an efficient internalization and recycling assay (29). It 
includes the water-soluble terbium cryptate donor (30), which is 
kinetically very stable, has an exceptionally bright luminescence 
when excited at 337 nm, and most importantly, does not exhibit 
a specific binding to cells (16). The O6-benzylguanine moiety is 
able to covalently label the ST (ST) developed by Keppler et al. 
(31) and has been used to monitor receptor internalization with 
fluorescence microscopy using classic fluorophores (31–33). 
The ST is a derivative of O6-guanine nucleotide alkyltransferase, 
which can covalently react with fluorescent-conjugated benzyl 
guanine substrates (14). To reduce non-specific labeling due to 
high substrate concentrations, a methyl-benzamide moiety was 
added to the benzylguanine group to further enhance its reactivity 
with the ST protein (34). This modification did not alter the 
quantum-yield of luminescence relative to the parent compound 
described by Xu et al. (30). Thus, DERET internalization assay 
relies on the use of a luminescent terbium cryptate derivative 
(SNAP-Lumi4-Tb) to label irreversibly the cells expressing the 
ST-GPCRs. Consequently, an efficient DERET should occur if 
cells expressing a lanthanide complex-labeled receptor on their 
surface are incubated with micromolar concentrations of an 
acceptor. Internalization of labeled receptors will prevent the 
interaction between donor and acceptor and reduce DERET 
signal intensity (Figure 1A). The receptor internalization assay 
includes five steps (Figure 1B).
Validation of the deRet Internalization 
Assay on Vasopressin V1a Receptors
To validate the strategy, we compared DERET to a classic method, 
which consists in evaluating receptors remaining at the cell sur-
face after agonist stimulation. HEK-293 cells stably expressing 
FIGURe 1 | deRet Internalization assay principle and protocol. (A) GPCRs at the cell surface and bearing the SNAP-Tag are labeled covalently with 
cell-impermeable SNAP-Lumi4®-Tb (energy donor, blue). When the receptor is at the cell surface, addition of a free energy acceptor (green dots) in micromolar 
concentrations to the cell medium leads to efficient energy transfer, quenching the donor luminescence and resulting in a high DERET signal (left). Following 
constitutive or agonist-induced internalization of the receptor, energy transfer to the acceptor is reduced, increasing the lifetime of the donor and hence 
decreasing the DERET (right). (B) The protocol of DERET-based internalization assay includes five steps: cell plating (step 1), cell membrane receptors labeling 
with SNAP-Lumi4-Tb (step 2), washing steps (step 3) to remove the substrate in excess, agonist stimulation, and fluorescein acceptor addition (step 4), and HTRF 
measurement (step 5) as described in the Section “Materials and Methods.”
FIGURe 2 | Comparison between deRet-based internalization assay 
and measure of receptor cell surface expression. (A) V1a internalization 
was monitored over time in response to 1 μM of AVP or (B) in the presence 
of increasing concentrations of AVP for 1 h at 37°C. Analysis was performed 
side-by-side using DERET assay (red line and right Y axis) and by measuring 
receptor expression levels at the cell surface after stimulation by AVP (black 
line and left Y axis) as described in the Section “Materials and Methods.” The 
data are mean ± SD from three independent experiments performed in 
triplicate.
FIGURe 3 | Real-time internalization and recycling of vasopressin V1a 
receptor. Following V1a internalization induced by AVP (1 μM) for 45 min, an 
excess of the antagonist SR49059 (10 μM) was added (at the time indicated 
by arrow) to stop internalization and to induce receptor recycling. Black line 
represents V1a internalization induced by AVP (increase 620/520 ratios). Blue 
line represents V1a internalization and recycling illustrated by an increase and 
a decrease in 620/520 ratios, respectively. Percent of ratios were plotted as a 
function of time and data represent mean ± SD from two independent 
experiments carried out in triplicates.
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the ST-vasopressin V1a receptor were incubated either in the 
presence of a constant AVP concentration for variable time to 
define kinetics of receptor internalization or in the presence of 
increasing concentration of AVP to establish the dose–response 
internalization curves. In a final step, cells were incubated with 
the non-cell-permeable SNAP-Lumi4-Tb in order to label exclu-
sively receptors which remain at the cell surface. Because DERET 
assays consist in monitoring the internalized receptor fraction, 
AVP stimulation resulted in a dramatic increase of fluorescence 
620/520 nm ratio (Figure 2A). By contrast, in the classic method, 
AVP stimulation resulted in a decrease of the fluorescence signal 
(Figure 2A), indicating receptor depletion from the cell surface. 
Fluorescence signals were plotted in function of the duration of the 
incubation with agonist and fitted with a one exponential decay 
equation routine. The half-time constants (t1/2) were respectively 
9.86 ± 0.004 min and 11.42 ± 0.009 min. Similarly, variations of 
the fluorescent signals were investigated in function of various 
AVP concentrations after 1 h incubation (Figure 2B). EC50 values 
determined after fitting experimental data were 2.7 ± 0.06 and 
7.7 ± 0.11 nM for DERET and the classic method, respectively. 
The consistency of the kinetics time constants and EC50 values 
obtained with the two different techniques proves the validity of 
the DERET strategy to investigate receptor internalization.
deRet Assay to study Receptor 
Recycling
Once internalized, receptors can either be degraded or rapidly 
recycled at the cell surface like the V1a receptor in response to 
AVP (35). To investigate this recycling, the internalization 
profile after agonist stimulation was compared to that upon the 
addition of an antagonist, in a second step. After the addition 
of an excess of SR49059 (10 μM), a selective antagonist of V1a 
receptor, the fluorescence ratio decreased to a level comparable to 
the one in non-stimulated cells (Figure 3). This decrease reflects 
the re-targeting of labeled ST-V1a receptors at the cell surface 
thus demonstrating the recycling of the V1a receptor. DERET is 
therefore a reliable strategy to follow agonist-induced receptor 
internalization and recycling.
deRet Assay Allows Characterizing 
Ligand Properties
Ligands can differ in their ability to activate distinct signaling 
cascades through the same receptor. This phenomenon is named 
functional selectivity or biased signaling. Recent studies have 
shown that the propensities of GPCR ligands to promote inter-
nalization do not necessarily correlate with agonist efficacy. For 
example, when considering opioïd receptor, some ligands can 
induce rapid receptor internalization while others such as mor-
phine do not (36). We analyzed δ opioïd receptor internalization 
using CHO cells stably expressing the ST-receptor (17). After 
optimizing the labeling of the receptor and signal measurement 
FIGURe 4 | deRet assay for identification of biased ligand of the δ opioïd receptor. (A) ST-δ receptor receptor internalization in the presence of the indicated 
δ receptor-ligands (10 μM) was measured after first incubating the plate at 4°C (t = 0) and then transferring it to room temperature for 5 h. Data represent mean ± SD 
from one representative experiment carried out in triplicates (B) Wide field fluorescence microscopy imaging of ST-δ receptor internalization. ST-δ receptor cells 
labeled with O6-Benzylguanine-Alexa-488 were treated with SNC162 (10 μM) or naloxone (10 μM) for 30 min at room temperature. Receptor internalization was 
visualized by fluorescence microscopy. Cells expressing labeled ST-δ receptor incubated in the presence of buffer were used as a negative control. (C) Dose–
response curves analysis of δ receptor. ST-δ receptor expressing cells were incubated with indicated concentrations of SNC162 (closed green circle), SNC80 (closed 
square), morphine (open circle), methadone (open square), DAMGO (closed triangle) and internalization measured after 1 h at 37°C Data represent mean ± SD from 
three independent experiments carried out in triplicates and fitted using non-linear regression dose–response log [ligand] versus response with three parameters.
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conditions (Figure S1 in Supplementary Material), we demon-
strated that SNC162 induced a dramatic receptor internalization 
while antagonists (naltrindole, naloxone, and naltrexazone) 
did not change the fluorescence ratio (Figure  4). Expression 
of the δ receptor at the cell membrane and its internalization 
were confirmed by fluorescence microscopy (Figure  4B). We 
next performed dose–responses experiments with some opi-
oïd receptors agonists to analyze their functional selectivity. 
We found that SNC162 and SNC80 promoted ST-δ receptor 
internalization in a dose-dependent manner (Figure 4C). EC50 
was 43.9 ± 0.04 nM for SNC162 and 18 ± 0.02 nM for SNC80 
(Figure  4C), values, which are similar to the ones reported 
with other methods (37, 38). In contrast, morphine and 
methadone did not trigger receptor internalization although 
they are full agonists of δ opioïd receptor for the Gi/o signaling 
pathway thereby demonstrating that they are biased agonists. 
FIGURe 5 | simultaneous detection of constitutive and CXCL12-induced internalization of CXCR4 and CXCR7 chemokine receptors. (A) Kinetic 
analysis of receptor internalization in HEK-293 cells stably expressing ST–CXCR4 or ST–CXCR7 and labeled with SNAP-Lumi4®-Tb. At the end of the labeling 
period, cells were transferred to 37°C (t = 0) and internalization was monitored in the presence or absence of 200 nM CXCL12. Results (mean ± SEM) were from 
three independent experiments performed in duplicate. (B) Constitutive internalization of ST–CXCR7 visualized by fluorescence microscopy. Cells expressing 
ST–CXCR7 were labeled with SNAP-red substrate at 4°C for 1 h and then were either held at 4°C for 1 h (upper panel) or transferred to 37°C for 1 h (lower panel) 
before being analyzed. (C) HEK-293 cells stably expressing ST–CXCR4 were incubated with buffer or CXCL12 (200 nM) alone or with 25 μM AMD3100 (a selective 
CXCR4 antagonist) or 25 μM chalcone 4 (a CXCL12 antagonist) for 1 h at 4°C. Internalization was then monitored at 37°C for 2 h. Results (mean ± SEM) were from 
three independent experiments. (d) Doses response curves of CXCR4, CXCR7, and CXCR7ΔCter internalization induced by CXCL12. Cells transiently expressing 
ST–CXCR4 (blue line), ST–CXCR7 (red line), or ST–CXCR7ΔCter (black line) were labeled with SNAP-Lumi4-Tb. Internalization was then measured in the presence 
of various CXCL12 concentrations for 1 h at 37°C. Data are fitted using non-linear regression dose–response log [agonist] versus response with four parameters. 
Results (mean ± SEM) were from three independent experiments performed in duplicate.
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As expected, the specific μ receptor agonist, DAMGO did not 
increase the fluorescence ratio, proving the specificity of the 
assay. Thus, DERET assay can be a relevant strategy to screen 
for biased agonists on internalization pathway.
Analyses by deRet of Agonist-
Independent GPCR Internalization
We sought to extend the DERET internalization assay to other 
receptors including those which display constitutive internaliza-
tion. To do so, we compared the internalization profiles of the 
CXCR7 and CXCR4 receptors, which share the same agonist 
(CXCL12) but respond to it differently (15, 39–41). CXCL12 is 
required during embryonic development and regulates many 
pathophysiological processes in adults (42) but the direct 
contribution of CXCR7 to CXCL12 functions remains largely 
unknown (43). In contrast to CXCR4, CXCR7 does not activate 
the typical Gαi pathways of chemokine receptors but signals 
through β-arrestins (44). Although both CXCR4 and CXCR7 
are internalized following stimulation with CXCL12, CXCR7 
also displays an atypical propensity to constitutively internalize. 
Thus, like other atypical chemokine receptors, CXCR7 is thought 
to act as a decoy receptor that helps to shape CXCL12 gradients 
and modulate CXCR4 function (2, 43, 45, 46). We investigated 
the internalization kinetics of CXCR4 and CXCR7 in HEK-293 
cells expressing chimeric receptors bearing ST (ST–CXCR4 or 
FIGURe 6 | the C-terminus of CXCR7 is essential for internalization. 
(A) Kinetic analysis of constitutive internalization of ST–CXCR7 (wild type; red 
curve) and ST–CXCR7ΔCter (lacking the C-terminus; black curve). 
HEK-293T cells transiently expressing one type of receptor were labeled with 
SNAP-Lumi4®-Tb. At the end of the labeling period (t = 0), internalization was 
followed over time at 37°C and plotted as a function of time. Results 
(mean ± SEM) were from three independent experiments performed in 
duplicate. (B) Cell surface expression levels of CXCR7 receptors in 
HEK-293T cells transiently expressing Flag-ST–CXCR7 or Flag-ST–
CXCR7ΔCter. Representative flow cytometry profiles of ST–CXCR7 (black 
histogram) and ST–CXCR7ΔCter expression (light gray histogram) were 
determined using anti-CXCR7 antibody. Filled gray histograms show staining 
with isotype control mAb. Receptor expression is shown as mean 
fluorescence intensity.
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ST–CXCR7). Both fusion proteins were expressed normally 
and showed no alteration of their functional properties (data 
not shown). Kinetic analyses of receptor internalization were 
performed at 37°C in the presence or absence of CXCL12 
(200  nM). CXCL12 stimulation greatly increased 620/520 
ratio in cells expressing ST–CXCR4 compared to the signal in 
non-stimulated cells (Figure 5A, blue dashed curve versus blue 
solid curve, respectively). These data indicate that CXCR4 was 
internalized solely in the presence of CXCL12. By contrast, we 
detected a high fluorescence ratio in cells expressing ST–CXCR7 
whether or not they were stimulated with CXCL12 (Figure 5A, 
red dashed curve versus red solid curve, respectively). These 
results indicate that CXCR7 can undergo ligand-dependent as 
well as ligand-independent internalization. It is noteworthy that 
the stimulation with CXCL12 induced a moderate change in the 
magnitude of the fluorescence ratio and slightly enhanced the 
CXCR7 internalization rate over time. These data extend previ-
ous findings showing that CXCL12 treatment has little effect on 
endogenous CXCR7 internalization in breast cancer cells (45). 
The constitutive internalization of the CXCR7 receptor was 
also confirmed in living cells by fluorescence microscopy after 
the cell surface-expressed ST-receptors were labeled with the 
cell-impermeable SNAP-Red fluorescent substrate (Figure 5B). 
Shifting labeled cells from 4 to 37°C for 1 h caused the labeled-
receptors to become highly concentrated intracellularly, con-
firming the propensity of the CXCR7 receptor to internalize in 
a ligand-independent manner (Figure  5B). CXCL12-induced 
ST–CXCR4 internalization was inhibited by AMD3100, a 
specific CXCR4 antagonist (47) and by chalcone 4, a CXCL12 
neutraligand (48), which provided further evidence that this 
internalization was specific to CXCL12-mediated receptor 
activation (Figure 5C, green and purple squares, respectively). 
CXCL12 stimulation of cells expressing either ST–CXCR4 or 
ST–CXCR7 promoted a dose-dependent receptor internalization 
(Figure 5D), with EC50 values of 4.15 ± 0.07 nM for ST–CXCR4 
and 9.7 ±  0.05  nM for ST–CXCR7, both of which agree with 
previous findings (15, 49, 50).
β-arrestins bind to the carboxyl terminus domain (C-ter) of 
CXCR7, which is essential for CXCL12-induced receptor inter-
nalization (39, 44, 51). Analyses performed in cells transiently 
expressing labeled receptors confirmed that ST–CXCR7 was 
constitutively internalized over time (Figure 6A, red curve) but 
that internalization of a receptor lacking the C-ter domain, ST–
CXCR7ΔCter, was almost completely abolished (Figures 5D and 
6A, black curve). Flow cytometry analysis showed that similar 
amounts of ST–CXCR7ΔCter and ST–CXCR7 proteins were 
present at the cell surface of transfected cells, thus excluding a 
defect in ST–CXCR7ΔCter expression (Figure 6B). The DERET 
assay allows investigating ligand-independent (constitutive) and 
-dependent internalization.
deRet Assay for high-throughput 
screening
To evaluate the suitability of DERET assay for HTS, we determined 
the Z′-factor, a performance indicator that takes into account 
both signal dynamic range and variation of experimental data 
(52). In HTS, a Z′-factor value between 0 and 0.5 is considered as 
acceptable. We calculated the Z′-factor value for the DERET assay 
based on CXCR4 internalization in ST–CXCR4 stably expressing 
cells stimulated with CXCL12 (Figure 7). We found a Z′-factor 
value of 0.45, which demonstrated the soundness of the DERET 
assay for screening compounds that can potentially modulate 
receptor internalization and expression at the cell surface.
extending deRet Assay to Class C 
GPCRs
Previous studies have reported that the class C mGluR5 GPCR 
undergoes a rapid internalization in response to glutamate (53). 
We analyzed mGluR5 internalization by performing kinetic and 
dose–response experiments using HEK-293 cells stably express-
ing the ST-receptor. We found that the glutamate agonist was 
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able to promote a time (Figure 8A) and concentration dependent 
(Figure 8B) internalization of mGluR5 (EC50 = 193.3 ± 0.03 μM) 
thus extending the DERET assay to class C GPCR.
CoNCLUsIoN
In conclusion, we provided compiling evidence that the 
DERET strategy is offering many advantages compared to other 
internalization assays and constitutes an attractive technology to 
monitor receptors internalization: (i) The assay is compatible with 
various receptors models as shown here for receptors of amino-
acids such as mGluR5 receptors, of peptides such as vasopressin 
or opioïd receptors, of proteins such as CXCR4 and CXCR7 
receptors and for receptors such as CXCR7 undergoing a ligand-
independent internalization and finally previously for receptors of 
bioamine (54); (ii) the technique is very easy to implement since it 
is based on a single labeling step by contrast to other conventional 
techniques based on multiple labeling steps separated by cold 
acid washing steps; (iii), the method is sensitive due to the use of 
cryptate of terbium, Lumi4-Tb. Its long lifetime allows to pass over 
the short-lived fluorescence resulting from auto-fluorescence of 
the biological samples or medium and directly excite the acceptor, 
dramatically decreasing the signal to noise ratio. DERET-based 
assay can also be extended to other tag-mediated labeling utilizing 
self-labeling proteins such as CLIP-Tag and Halo-Tag, which are 
reacting covalently with an exogenously supplied substrate that 
is linked to different fluorescent dyes thereby multiplying the 
labeling possibilities; (iv), it is a quantitative method to estimate 
the amplitude of the internalization process and compatible with 
kinetics and dose–response experiments, allowing characterization 
of pharmacological parameters and the identification of biased 
agonists; (v), the receptor is directly and covalently labeled 
allowing tracking the receptor itself and not the complex between 
the receptor and the ligand. This is particularly important to study 
receptor recycling or degradation since the fusion of endosomes 
to lysosome induces an acidification of the vesicular medium and 
the dissociation of the ligand/receptor complex; (vi), the reduced 
number of steps of the DERET strategy and the high signal/noise 
ratio make this assay suitable for HTS as supported by the Z′-value 
characterized in this study. The major drawback of DERET is 
that it relies on chimeric receptors and is not compatible with 
the investigation of endogenous receptors. Nevertheless, to our 
knowledge, no effect of self-labeling domains (ST, CLIP-tag, 
HaloTag) have been reported so far on the pharmacology of 
the receptors (14, 16, 55–57). It is also noteworthy that DERET 
does not allow an absolute but a relative quantification, making 
difficult the comparison of the DERET signal obtained on different 
receptor models. Moreover, in the time course of an experiment, 
neo-synthesized receptors that have reached the cell surface will 
not be considered since they have not been labeled. This limitation 
could eventually impact the accuracy of the quantification of the 
internalization in case of large over-expression of the receptor.
FIGURe 8 | Real-time internalization of mGluR5. (A) ST-mGluR5 
expressed at the cell surface were labeled with SNAP-Lumi4-Tb. Cells were 
subsequently incubated with an excess of acceptor in the presence of 1 μM 
of glutamate (closed square) or in absence of agonist (open square). 
Internalization of mGluR5 was measured at 37°C over time. Data represent 
mean ± SD from three independent experiments performed in duplicate. 
Data were fitted using one phase association equation. (B) Dose–response 
curve for mGluR5 in response to glutamate. Cells were stimulated for 1 h 
with increasing concentrations of glutamate and internalization was 
monitored. Data represent mean ± SD from three independent experiments 
performed in triplicate and were fitted using non-linear regression dose–
response log (agonist) versus response with three parameters.
FIGURe 7 | Z′-factor determination in CXCR4 internalization assays. 
HEK-293 cells stably expressing ST–CXCR4 were labeled with SNAP-
Lumi4®-Tb. At the end of the labeling period (t = 0), cells were incubated with 
an excess of acceptor and stimulated or not with 200 nM of CXCL12. 
Internalization of CXCR4 was followed at 37°C for 1 h as described in the 
Section “Materials and Methods.” The Z′-factor was obtained according to 
the published methods by Zang et al. (52). The scatter plot represents the 
48-well positive controls data (with CXCL12, open circle) and the 48-well 
negative control data (with buffer, closed circle). Solid lines represent the 
mean internalization signal and dashed lines represent three SD above and 
below.
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